Search

Adolescents and young adults (AYA)

Spotlight on AYAAdolescents and young adults (AYA) with hematologic diseases are a unique group with special characteristics and needs. In recent years, the challenges related to the management of AYA (particularly in relation to cancer) have increasingly been recognized.

Read more

From Plans to Action: European Cancer Summit

From Plans to Action:  European Cancer Summit (Brussels-Hybrid, November 17-18, 2021) 
November 17- 18 marks the first anniversary of EHA’s membership to the European Cancer Organisation (ECO), as well as the event dates for the 2021 European Cancer Summit.

Read more

EHA pays tribute to Professor Jacques-Louis Binet (1932–2024)

We would like to pause to acknowledge the passing of Professor Jacques-Louis Binet, a pioneer in clinical and biological research and an exceptional personality in hematology, on December 17, 2024.

Read more

Collaboration with the EMA on Joint Clinical Assessments and Joint Scientific Consultations under the HTA Regulation

The European Hematology Association (EHA) welcomes the draft Implementing Act laying down procedural rules for the exchange of information between the Health Technology Assessment (HTA) Coordination Group, the European Commission, and the European Medicines Agency (EMA).

Read more

Training vital for new era of patient-centric healthcare

Christine Chomienne, president of the European Hematology Association (EHA), was speaking at the third annual conference of the European Alliance for Personalised Medicine (EAPM) – a Brussels-based organization that brings together stakeholders from academia, through research,…

Read more

Health Technology Assessment (HTA)

Every European citizen should have access to the best quality medical care at the best possible price. Pan-European cooperation on health technology assessments (HTA) is essential for such aspirations.

Read more

International Call to Action to Alleviate Drug Shortages

The common call to action seeks first to raise awareness of shortages of drugs among hematologists.

Read more